AI Pedestrian Traffic Safety System

According to the U.S. Department of Transportation (USDOT) and the National Highway Traffic Safety Administration (NHTSA), the number of traffic fatalities in the United States was 36,096 in 2019, which is more than 11.17 deaths per 100,000 population. In 2019, more than 240 people died in traffic accidents in the city of Los Angeles alone, with pedestrians accounting for more than half (55%) of these deaths. These numbers underscore the criticality of improving national pedestrian and bicyclist safety. Until recently, there was no effective automated system for monitoring the movement of these vulnerable groups, making it difficult to determine which safety interventions were most effective. Understanding the need for clear measurement, researchers from the Mineta Transportation Institute developed and implemented a new automated system using artificial intelligence (AI) and computer vision to monitor, track, and count the movement of pedestrians in major urban areas using existing traffic cameras. Led by Dr. Mohammad Pourhomayoun, the team created the AI Pedestrian Traffic Safety System, which collects and processes this data in real time to enable dynamic traffic control. The system is already being implemented and tested in downtown Los Angeles, and because it requires no new equipment, it can be cost-effectively scaled over time to improve safety in LA and beyond

Validation of Calprotectin As a Novel Biomarker For The Diagnosis of Pleural Effusion: a Multicentre Trial

Discriminating between malignant pleural effusion (MPE) and benign pleural effusion (BPE) remains difficult. Thus, novel and efficient biomarkers are required for the diagnosis of pleural effusion (PE). The aim of this study was to validate calprotectin as a diagnostic biomarker of PE in clinical settings. A total of 425 patients were recruited, and the pleural fluid samples collected had BPE in 223 cases (53.7%) or MPE in 137 patients (33%). The samples were all analysed following the same previously validated clinical laboratory protocols and methodology. Calprotectin levels ranged from 772.48 to 3,163.8 ng/mL (median: 1,939 ng/mL) in MPE, and 3,216-24,000 ng/mL in BPE (median: 9,209 ng/mL; p < 0.01), with an area under the curve of 0.848 [95% CI: 0.810-0.886]. For a cut-off value of </= 6,233.2 ng/mL, we found 96% sensitivity and 60% specificity, with a negative and positive predictive value, and negative and positive likelihood ratios of 96%, 57%, 0.06, and 2.4, respectively. Multivariate analysis showed that low calprotectin levels was a better discriminator of PE than any other variable [OR 28.76 (p < 0.0001)]. Our results confirm that calprotectin is a new and useful diagnostic biomarker in patients with PE of uncertain aetiology which has potential applications in clinical practice because it may be a good complement to cytological methods

For Returning Military Vets, Transportation Is Key to Reintegration as Civilians

The report concludes that returning military veterans and support agencies must consider transportation access to essential services, without which returning military veterans can have a difficult time reintegrating into civilian life. In fact, transit-oriented development (TOD) may provide a viable option for veterans with disabilities to help them meet their postservice needs independently and successfully, which could serve to ultimately reduce homelessness and other challenges experienced by this population of Americans

Expansion of different subpopulations of CD26 ?/low T cells in allergic and non-allergic asthmatics

CD26 displays variable levels between effector (TH17 >> TH1 > TH2 > Treg) and naive/memory (memory > naive) CD4(+) T lymphocytes. Besides, IL-6/IL(-)6R is associated with TH17-differentiation and asthma severity. Allergic/atopic asthma (AA) is dominated by TH2 responses, while TH17 immunity might either modulate the TH2-dependent inflammation in AA or be an important mechanism boosting non-allergic asthma (NAA). Therefore, in this work we have compared the expression of CD26 and CD126 (IL-6Ralpha) in lymphocytes from different groups of donors: allergic (AA) and non-allergic (NAA) asthma, rhinitis, and healthy subjects. For this purpose, flow cytometry, haematological/biochemical, and in vitro proliferation assays were performed. Our results show a strong CD26-CD126 correlation and an over-representation of CD26(-) subsets with a highly-differentiated effector phenotype in AA (CD4(+)CD26(-/low) T cells) and NAA (CD4(-)CD26(-) gammadelta-T cells). In addition, we found that circulating levels of CD26 (sCD26) were reduced in both AA and NAA, while loss of CD126 expression on different leukocytes correlated with higher disease severity. Finally, selective inhibition of CD26-mRNA translation led to enhanced T cell proliferation in vitro. These findings support that CD26 down-modulation could play a role in facilitating the expansion of highly-differentiated effector T cell subsets in asthma

Comparison of Image Acquisition Techniques in Four-Dimensional Flow Cardiovascular MR on 3 Tesla in Volunteers and Tetralogy of Fallot Patients

Four-dimensional phase-contrast (PC) velocity-encoded flow magnetic resonance imaging (4D flow MRI) is a potentially valuable tool for studying cardiovascular hemodynamics for disease monitoring and/or treatment planning. In this study we compared the performance of two 4D flow MRI pulse sequences - echo-planar imaging (EPI) and segmented gradient-echo (turbo-field-echo or TFE on vendor's platform) - on a clinical 3T system in 6 human subjects including 3 patients with Tetralogy of Fallot (TOF). For aortic flow rate, the coefficients of variation (COV) between 2D and 4D EPI were 7.0% and 7.7% for controls and patients respectively. The corresponding COV between 2D and 4D TFE were 19.0% and 18.3% for controls and patients respectively. The COV between 4D TFE and 4D EPI were larger than 18.7% in kinetic energy analysis. 4D EPI demonstrated acceptable accuracy of intra-cardiac flow quantification, which was also shown in the ex-vivo phantom measurements

Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias

Neurodegenerative dementias are progressive diseases that cause neuronal network breakdown in different brain regions often because of accumulation of misfolded proteins in the brain extracellular matrix, such as amyloids or inside neurons or other cell types of the brain. Several diagnostic protein biomarkers in body fluids are being used and implemented, such as for Alzheimer\xe2\x80\x99s disease. However, there is still a lack of biomarkers for co-pathologies and other causes of dementia. Such biofluid-based biomarkers enable precision medicine approaches for diagnosis and treatment, allow to learn more about underlying disease processes, and facilitate the development of patient inclusion and evaluation tools in clinical trials. When designing studies to discover novel biofluid-based biomarkers, choice of technology is an important starting point. But there are so many technologies to choose among. To address this, we here review the technologies that are currently available in research settings and, in some cases, in clinical laboratory practice. This presents a form of lexicon on each technology addressing its use in research and clinics, its strengths and limitations, and a future perspective